Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2017 18:19 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016

Hemispherx Biopharma Management Team Continues Its Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value Conference Call...
March 06, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017

PHILADELPHIA, March 06, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it has met a major milestone, the commencement of...
February 02, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering

PHILADELPHIA, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced today that it has entered into definitive agreements with several...
January 26, 2017 10:51 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe

PHILADELPHIA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access...
January 11, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients

PHILADELPHIA, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that the rintatolimod European early access program (EAP) designed...
November 21, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma to Present at the 9th Annual LD Micro Main Event

PHILADELPHIA, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that it will be presenting at the 9th annual LD Micro Main Event...
November 14, 2016 16:36 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended September 30, 2016

PHILADELPHIA, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announces the filing of its Quarterly Report and its financial results for the nine months ended September 30, 2016....
November 10, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15, 2016

PHILADELPHIA, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 third quarter financial...
November 08, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the Power of Immune Response to Treat Disease: Biotech Bounce Back”

PHILADELPHIA, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has posted an article from Corporate America News magazine, released on...
October 31, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/ME

51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% in exercise tolerance Data presented at the 12th...